肺动脉高血压在全身性硬化症中的多方面的问题
Cosimo Bruni1, Christophe Guignabert2, Mirko Manetti3
1Division of Rheumatology, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
The Lancet. Rheumatology
|January 27, 2024
概括
系统性硬化症患者因心肺问题,特别是肺高血压的高死亡率. 早期检测和针对血管,免疫和炎症因素的整体治疗对于更好的结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
背景情况:
- 心肺复杂症是系统性硬化症的主要死亡原因.
- 肺高血压 (PH) 显著增加这些患者的死亡率和发病率.
- 系统性硬化症相关的PH包括肺动脉高血压 (PAH) 和由于间歇性肺病 (PH-ILD) 的PH.
研究的目的:
- 探索病原遗传机制与系统性硬化症PH的治疗点之间的联系.
- 突出目前在管理系统性硬化症相关PH的未满足需求.
- 强调需要一个全面的治疗策略.
主要方法:
- 这种观点综合了当前关于系统性硬化症PH病理生物学知识.
- 它审查了现有的治疗策略,并确定了护理方面的差距.
- 作者专注于早期诊断和分类方面的挑战.
主要成果:
- 与全身性硬化症相关的PH具有明显的病原遗传特征,导致与异常性PAH相比,预后较差.
- 早期查和检测PH是关键的,但往往缺乏.
- 从PH-ILD区分PAH与ILD仍然是一个诊断挑战.
结论:
- 需要采用整体治疗方法,解决血管,免疫和炎症方面的问题.
- 需要为系统性硬化症中PH亚型制定一致的诊断标准.
- 对系统性硬化症相关PH的向治疗进行进一步的研究是必不可少的.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
180
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
180
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
158
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
158
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
216
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
216
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K


